系统性硬化症的医疗资源利用与经济负担:一项系统综述
该系统综述检索MEDLINE和EMBASE至2021年1月20日,纳入34项研究(20项横断面、11项队列、3项病例对照),对系统性硬化症(SSc)的经济影响与医疗资源利用进行叙述性综合。SSc年度总费用在美国为14959至23268美元,加拿大为10673至18453加元,欧洲为4607至30797欧元,大洋洲为7060至11607澳元。SSc相关间质性肺病和肺动脉高压的年费用分别为31285至55446美元和44454至63320美元。
要点
- SSc年度总费用因地区而异:美国14959至23268美元,欧洲4607至30797欧元。
- SSc相关间质性肺病年费用31285至55446美元,肺动脉高压44454至63320美元。
- 纳入研究方法差异大,SSc相关并发症增加经济负担且因地理位置和可及性而异。
核心结论
- SSc给患者和医疗资源带来显著经济负担,相关并发症增加经济负担且因地理位置和可及性而异。
研究设计与样本
- 系统综述检索MEDLINE和EMBASE自建库至2021年1月20日,纳入提供SSc总费用、直接或间接费用信息的研究。
- 共纳入34项研究,包括20项横断面研究、11项队列研究和3项病例对照研究。
- 采用Joanna Briggs Institute横断面和病例系列清单以及Newcastle-Ottawa队列和病例对照量表进行偏倚风险评估,计划进行叙述性综合。
主要发现
- 检索到1778篇文献,最终纳入34项研究。
- 纳入研究采用不同的费用计算方法,包括基于患病率的疾病成本法和健康资源单位成本分析。
- SSc年度总费用在美国为14959至23268美元,在加拿大为10673至18453加元,在欧洲为4607至30797欧元,在大洋洲为7060至11607澳元。
- SSc相关间质性肺病年费用为31285至55446美元,肺动脉高压年费用为44454至63320美元。
关键数值与推荐
- SSc年度总费用:美国14959至23268美元,加拿大10673至18453加元,欧洲4607至30797欧元,大洋洲7060至11607澳元。
- SSc相关间质性肺病年费用31285至55446美元,肺动脉高压年费用44454至63320美元。
临床怎么用
- 原文未据此给出推荐。
局限性
- 纳入研究的费用计算方法差异很大。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Systemic sclerosis (SSc) is characterized by vasculopathy, fibrosis of skin and internal organs, and autoimmunity with complications including interstitial lung disease, pulmonary hypertension, and digital ulcers with substantial morbidity and disability. Patients with SSc may require considerable healthcare resources with economic impact. The purpose of this systematic review was to provide a narrative synthesis of the economic impact and healthcare resource utilization associated with SSc. METHODS: MEDLINE and EMBASE were searched from inception to 20 January 2021. Studies were included if they provided information regarding the total, direct and indirect cost of SSc. The cost of SSc subtypes and associated complications was determined. Risk of bias assessments through the Joanna Briggs Institute cross-sectional and case series checklists, and the Newcastle-Ottawa Cohort and Case-Control study scales were performed. A narrative synthesis of included studies was planned. RESULTS: The number of publications retrieved was 1778, of which 34 were included representing 20 cross-sectional, 11 cohort, and three case-control studies. Studies used various methods of calculating cost including prevalence-based cost-of-illness approach and health resource units cost analysis. Overall SSc total annual cost ranged from USD $14 959 to $23 268 in USA, CAD $10 673 to $18 453 in Canada, €4607 to €30 797 in Europe, and AUD $7060 to $11 607 in Oceania. Annual cost for SSc-associated interstitial lung disease and pulmonary hypertension was USD $31 285-55 446 and $44 454-63 320, respectively. CONCLUSION: Cost-calculation methodology varied greatly between included studies. SSc represents a significant patient and health resource economic burden. SSc-associated complications increase economic burden and are variable depending on geographical location and access.
引用
- Martin Calderon L, Chaudhary M, Pope JE, et al. Healthcare utilization and economic burden in systemic sclerosis: a systematic review. Rheumatology (Oxford). 2022. PMID: 34849627. doi:10.1093/rheumatology/keab847
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。